{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:45:59Z","timestamp":1787021159584,"version":"build-2736575974"},"reference-count":16,"publisher":"Royal College of Psychiatrists","issue":"1","license":[{"start":{"date-parts":[[2018,1,2]],"date-time":"2018-01-02T00:00:00Z","timestamp":1514851200000},"content-version":"unspecified","delay-in-days":1097,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Psychiatry"],"published-print":{"date-parts":[[2015,1]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>From its first use 3,4,-methylenedioxymethamphetamine (MDMA) has been recognised as a drug with therapeutic potential. Research on its clinical utility stopped when it entered the recreational drug scene but has slowly resurrected in the past decade. Currently there is enough evidence for MDMA to be removed from its Schedule 1 status of \u2018no medical use\u2019 and moved into Schedule 2 (alongside other misused but useful medicines such as heroin and amphetamine). Such a regulatory move would liberate its use as a medicine for patients experiencing severe mental illnesses such as treatment-resistant post-traumatic stress disorder.<\/jats:p>","DOI":"10.1192\/bjp.bp.114.152751","type":"journal-article","created":{"date-parts":[[2015,1,5]],"date-time":"2015-01-05T14:54:17Z","timestamp":1420469657000},"page":"4-6","source":"Crossref","is-referenced-by-count":29,"title":["Making a medicine out of MDMA"],"prefix":"10.1192","volume":"206","author":[{"given":"Ben","family":"Sessa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Nutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"170","published-online":{"date-parts":[[2018,1,2]]},"reference":[{"key":"S000712500023729X_ref12","article-title":"The effects of acutely administered 3,4-methylenedioxymethamphetamine on spontaneous brain function in healthy volunteers measured with arterial spin labeling and blood oxygen level-dependent resting state functional connectivity","volume":"10","author":"Carhart-Harris","year":"2014","journal-title":"Biol Psychiatry"},{"key":"S000712500023729X_ref8","doi-asserted-by":"crossref","unstructured":"Hysek CM , Schmid Y , Simmler LD , Domes G , Heinrichs M , Eisenegger C , et al. MDMA enhances emotional empathy and prosocial behavior. Soc Cogn Affect Neurosci 2013; Oct 23 (Epub ahead of print).","DOI":"10.1093\/scan\/nst161"},{"key":"S000712500023729X_ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-014-3570-x"},{"key":"S000712500023729X_ref5","doi-asserted-by":"publisher","DOI":"10.1002\/pnp.216"},{"key":"S000712500023729X_ref13","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2389"},{"key":"S000712500023729X_ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2013.11.030"},{"key":"S000712500023729X_ref4","doi-asserted-by":"publisher","DOI":"10.1177\/0269881113495119"},{"key":"S000712500023729X_ref15","volume-title":"Suicide Data Report 2012","author":"Kemp","year":"2013"},{"key":"S000712500023729X_ref14","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.108.050344"},{"key":"S000712500023729X_ref1","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.1986.10472364"},{"key":"S000712500023729X_ref10","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2014.12"},{"key":"S000712500023729X_ref3","doi-asserted-by":"publisher","DOI":"10.1177\/0269881112456611"},{"key":"S000712500023729X_ref2","article-title":"The safety and efficacy of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study","volume":"25","author":"Mithoefer","year":"2010","journal-title":"J Psychopharmacol"},{"key":"S000712500023729X_ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-014-3528-z"},{"key":"S000712500023729X_ref16","unstructured":"Multidisciplinary Association for Psychedelic Studies (MAPS). Protocol MAA-1: A Placebo-Controlled, Randomized, Blinded, Dose Finding Phase 2 Pilot Safety Study of MDMA Assisted Therapy for Social Anxiety in Autistic Adults. Multidisciplinary Association for Psychedelic Studies (MAPS), 2013 (http:\/\/www.maps.org\/research\/mdma\/MAA1_FINAL_Protocol_22Feb13_redact.pdf)."},{"key":"S000712500023729X_ref6","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2014.80"}],"container-title":["British Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S000712500023729X","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T03:33:34Z","timestamp":1566185614000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S000712500023729X\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S000712500023729X"],"URL":"https:\/\/doi.org\/10.1192\/bjp.bp.114.152751","relation":{},"ISSN":["0007-1250","1472-1465"],"issn-type":[{"value":"0007-1250","type":"print"},{"value":"1472-1465","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1]]}}}